Cutia Therapeutics

As of December 31, 2025, Cutia Therapeutics carries a market capitalization of 1.65B, placing it among publicly traded companies globally. Its enterprise value stands at 1.13B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Cutia Therapeutics's next confirmed earnings release is scheduled for March 30, 2027.

As of December 31, 2025, Cutia Therapeutics has 363.37M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Cutia Therapeutics maintains a current ratio of 3.87, meaning it holds 3.9x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 22, 2026, Cutia Therapeutics's stock has declined approximately 91.86% over the past 52 weeks. The 50-day moving average sits at 1.42, while the 200-day moving average is 3.42.

As of December 31, 2025, Cutia Therapeutics holds 877.23M in cash and equivalents against 353.22M in total debt, resulting in a net debt position of -15.35M. Total book value stands at 985.22M, with working capital of 860.19M providing operational flexibility.